Opinion|Videos|October 14, 2024
Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy
Key Takeaways
- Route of administration impacts patient compliance and convenience, influencing the choice of PD-1/PD-L1 agents.
- Duration of therapy affects patients' quality of life and is a key consideration in treatment selection.
Panelists discuss how various factors, such as route of administration, duration of therapy, safety, efficacy, and cost, could influence the selection of different PD-1/PD-L1 agents once they receive approval, highlighting the importance of these considerations in optimizing patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors could influence the choice between different PD-1/PD-L1 agents if they are eventually approved [ie, route of administration, duration of therapy, safety, efficacy, place of administration, drug preservation, biomarkers, cost, etc]?
Advertisement
Related to this article
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to pre-biopsy 68Ga-PSMA-PET program
2
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
3
Brian Mazzarella, MD, reviews early data on water vapor therapy for localized prostate cancer
4
Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer
5